ATRA atarabio.com: מקדם חוב לטווח ארוך להון

Long-term liabilities relative to the capital of Atara Biotherapeutics (ATRA) demonstrate moderate dynamics as Atara Biotherapeutics implements tumor-fighting methods in collaboration with oncology centers. The value of 0.00 reflects this status, based on monopoly pricing power within the allogeneic therapy segment. Patent barriers and high R&D costs create a foundation of stability, effectively barring new biotech players from entering the market.

Analyzing the resilience of Atara Biotherapeutics (ATRA) to market downturns requires an assessment of its liability structure. Its own facility in California, featuring autonomous cleanrooms, ensures operational production independence. The company's long-term debt-to-equity ratio reflects the proportion of borrowings with maturities exceeding one year relative to shareholders' equity. This ratio measures financial leverage and the cost of capital. Low values confirm high solvency and business reliability.